Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

IMMX
Immix Biopharma, Inc. Common Stock
stock NASDAQ

Market Open
Jul 27, 2026 3:11:32 PM EDT
8.89USD+4.343%(+0.37)1,416,109
8.88Bid   10.15Ask   1.27Spread
Pre-market
Jul 27, 2026 9:27:30 AM EDT
8.62USD+1.174%(+0.10)446
After-hours
Jul 24, 2026 4:50:30 PM EDT
8.52USD+0.059%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
08:07AM EST  ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up   Benzinga
08:00AM EST  -- Manufactured IMX-110 to be utilized in both clinical trials: -- 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (STS) -- 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors   GlobeNewswire Inc
Jan 27, 2022
05:01AM EST  41 Biggest Movers From Yesterday   Benzinga
Jan 25, 2022
12:17PM EST  Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies   Benzinga
10:15AM EST  IMX-110 + anti-PD-1 Combination Produced Extended Median Survival   GlobeNewswire Inc
Jan 19, 2022
08:02AM EST  ImmixBio Announces IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data; Says Data Demonstrates100% Completion Of Planned Treatment Cycles   Benzinga
08:00AM EST  -- 100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trial -- IMX-110 is in clinical development as a monotherapy for soft tissue sarcoma (STS), a $3 billion market expected to grow to $6.5 billion by 2030   GlobeNewswire Inc
Jan 12, 2022
02:57PM EST  Mid-Afternoon Market Update: Nasdaq Rises 50 Points; Jefferies Shares Drop   Benzinga
12:32PM EST  Mid-Day Market Update: Crude Oil Rises 2%; Philips Shares Plummet   Benzinga
10:29AM EST  Immix Biopharma, Inc. (IMMX) shares are soaring more than 25 percent on Wednesday morning trade after the company reported a positive response for its lead candidate IMX -110 in first-line - therapy-resistant cancer, surpassing the standard of care in mice model.   RTTNews
09:12AM EST  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Jan. 12, 2022: BIIB, AMD, RBLX, LYFT, IMMX   Benzinga
08:04AM EST  ImmixBio IMX-110 Produced 50% Positive Response Rate In First-Line-Therapy-Resistant Cancer, Surpassing The Standard Of Care In Mice Study   Benzinga
08:00AM EST  ImmixBio IMX-110 Produced 50% Positive Response Rate in   GlobeNewswire Inc
Jan 10, 2022
09:37AM EST  Immix Biopharma Shares Halted On Circuit Breaker To Upside; Up 10%   Benzinga
09:22AM EST  Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 10, 2022: JPM, XSPA, DSS, NNDM, IMMX   Benzinga
07:41AM EST  The Week Ahead In Biotech (Jan 10-15): JPMorgan Healthcare Conference Front And Center, Preannouncements Keep Coming   Benzinga
Jan 6, 2022
09:00AM EST  Immix Biopharma, Inc. (Nasdaq: IMMX) (ImmixBio or the Company), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the IMMX Investors Day Event, to be held on February 1, 2022, and the launch of an online Q&A platform for all shareholders to submit questions in advance.   GlobeNewswire Inc
Jan 4, 2022
10:30AM EST  Shares of Immix Biopharma, Inc. (IMMX) are gaining nearly 25% on Tuesday morning. The other day, the U.S. Food and Drug Administration granted Rare Pediatric Disease (RPD) designation for Immix Biopharma's IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.   RTTNews
10:10AM EST  Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Drops To 58.7   Benzinga
Jan 3, 2022
02:39PM EST  Mid-Afternoon Market Update: Dow Surges 150 Points; Applied Therapeutics Shares Slide   Benzinga
12:55PM EST  EXCLUSIVE: ImmixBio Chief Executive Officer, Ilya Rachman, M.D., Ph.D. Says Co Does Not Need To Raise More Money For A Year, Co Has Enough Money To Fund Its Operations   Benzinga
12:47PM EST  EXCLUSIVE: ImmixBio Chief Executive Officer, Ilya Rachman, M.D., Ph.D. Now Interviewing On Benzinga's Live YouTube TV   Benzinga
12:09PM EST  Mid-Day Market Update: Gold Down 1%; Immix Biopharma Shares Spike Higher   Benzinga
11:20AM EST  EXCLUSIVE: ImmixBio Chief Executive Officer, Ilya Rachman, M.D., Ph.D. To Appear On Benzinga's Live YouTube TV At 12:45 p.m. ET On Monday   Benzinga
10:06AM EST  Mid-Morning Market Update: Markets Edge Higher; Tesla Q4 Deliveries Top Estimates   Benzinga
08:50AM EST  Biopharmaceutical company Immix Biopharma, Inc. (IMMX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.   RTTNews
08:29AM EST  FDA Approves Immix Biopharma Rare Pediatric Disease Designation For IMX-110; Stock Surges   RTTNews
08:03AM EST  FDA Approves Immix Biopharma Rare Pediatric Disease Designation For IMX-110 As A Treatment For Life-Threatening Pediatric Cancer In Children   Benzinga
08:00AM EST  U.S. Food and Drug Administration Approves Immix Biopharma Rare   GlobeNewswire Inc
Dec 20, 2021
04:16PM EST  Immix Biopharma, Inc. Announces Closing of Initial Public Offering   GlobeNewswire Inc
07:25AM EST  The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET).   RTTNews
Dec 19, 2021
12:54PM EST  The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week   Benzinga
Dec 16, 2021
11:32AM EST  Immix Biopharma Shares Open For Trade At $5; IPO Priced $5/Share   Benzinga
09:30AM EST  Immix Biopharma Shares Will Open For Quote At 10:35 a.m. EST, Expected To Open For Trade After 10:45 a.m. EST; IPO Priced $5/Share   Benzinga
08:20AM EST  The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street   Benzinga
Dec 15, 2021
06:00PM EST  Immix Biopharma, Inc. Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC